Literature DB >> 1967808

Vigabatrin in infantile spasms.

C Chiron, O Dulac, D Luna, L Palacios, S Mondragon, D Beaumont, J P Mumford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1967808     DOI： 10.1016/0140-6736(90)90660-w

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Treatment of infantile spasms: the ideal and the mundane.

Authors:  Tallie Z Baram
Journal:  Epilepsia       Date:  2003-08       Impact factor: 5.864

2.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 3.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 6.  Tuberous sclerosis.

Authors:  D W Webb; J P Osborne
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

Review 7.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

8.  New antiepileptic drugs: lacosamide, rufinamide, and vigabatrin.

Authors:  Laura A Strom; Susan Koh; Lauren Frey
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

9.  Effects of blocking GABA degradation on corticotropin-releasing hormone gene expression in selected brain regions.

Authors:  V Tran; C G Hatalski; X X Yan; T Z Baram
Journal:  Epilepsia       Date:  1999-09       Impact factor: 5.864

Review 10.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.